Table 8.
Noncarrier study exploratory clinical efficacy assessments: change from parent study baseline to extension week 52
| 3002 ApoE ε4 noncarrier study | ||||
|---|---|---|---|---|
| PBO + BAP 0.5 (n = 38) | BAP 0.5 + BAP 0.5 (n = 62) | PBO + BAP 1.0 (n = 33) | BAP 1.0 + BAP 1.0 (n = 53) | |
| ADAS-Cog, LS mean (SE) | 12.44 (1.70) | 10.38 (1.35) | 10.54 (1.82) | 10.31 (1.36) |
| LS mean difference | –2.05; P = 0.345 | –0.22; P = 0.922 | ||
| DAD, LS mean (SE) | –29.52 (3.48) | –28.00 (2.77) | –20.41 (3.74) | –23.21 (2.80) |
| LS mean difference | 1.53; P = 0.733 | –2.81; P = 0.550 | ||
| NPI, LS mean (SE) | 4.99 (2.60) | –0.01 (2.05) | 4.23 (2.80) | 6.57 (2.08) |
| LS mean difference | –4.99; P = 0.133 | 2.34; P = 0.505 | ||
| MMSEa, LS mean (SE) | –4.86 (0.56) | –4.13 (0.44) | –4.63 (0.58) | –4.51 (0.46) |
| LS mean difference | 0.73; P = 0.309 | 0.12; P = 0.872 | ||
ADAS-Cog Alzheimer’s Disease Assessment Scale—Cognitive Subscale, ApoE apolipoprotein E, BAP bapineuzumab, DAD Disability Assessment Scale for Dementia, LS least squares, MMSE Mini-Mental State Examination, NPI Neuropsychiatric Inventory, PBO placebo, SE standard error of the mean
aDifference in MMSE score was between parent study baseline and extension study week 45